Eysz Announces Investment by Epilepsy Alliance America to Advance its AI-based Epilepsy Management Platform
Eysz is developing an AI-based software solution that analyzes passive eye-movements from compatible eye-tracking systems to assist clinicians in understanding their patient's seizure burden and neurocognitive side effects, enabling them to create a more personalized care plan. Current standard of care relies on patient-report data for epilepsy treatment outcomes which is < 50% accurate and does not give doctors the reliable data they need to accurately measure treatment outcomes. For people with epilepsy, this cycle results in a prolonged trial-and-error treatment cycle leading to poor quality of life, poor treatment adherence, and excessive costs.
Rachel Kuperman, MD, Founder & CEO of Eysz, stated, "We are humbled by the Epilepsy Alliance America for their investment, which demonstrates a vote of confidence in our team to bring forward a solution with the potential to improve outcomes for people with epilepsy. We chose to raise this capital via Reg CF because we saw it as an opportunity to bring all stakeholders in the epilepsy community together on a shared issue that impacts outcomes for everyone."
Jeff Sinsebox, President of Epilepsy Alliance America stated, "This investment in Eysz, which supports the development of a patient-centric management system that can potentially help improve outcomes, is in line with our mission to promote the independence and quality of life for people with epilepsy and their families. The Alliance was founded by the uniting of multiple leading grassroots epilepsy organizations with a shared mission to provide direct support to people with epilepsy and the people who care for them. Eysz's equity crowdfunding campaign is an opportunity for the community to come together in the same spirit."
Epilepsy, which is characterized by recurrent seizures, is one of the most common and expensive neurological disorders. According to the World Health Organization, epilepsy is the most common serious brain disorder worldwide with no age, racial, social class, national or geographic boundaries. Globally, more than 70 million people have epilepsy. The U.S. Centers for Disease Control & Prevention (CDC) estimates that 3.4 million people in the United States are affected by epilepsy.
Eysz is a startup developing a digital health platform to enable personalized medicine for neurological disorders starting with epilepsy, one of the most common and expensive neurological disorders. The goal of epilepsy treatment is to stop seizures with minimal side effects as quickly as possible. However, doctors do not have the reliable data they need to accurately measure treatment outcomes. Eysz's unique AI-based software analyzes passive eye-movements from compatible eye-tracking systems to assist clinicians in understanding their patient's seizure burden and neurocognitive side effects enabling them to create a more personalized care plan, potentially resulting in better quality of life, improved treatment adherence, and lower costs. To learn more, visit www.eyszlab.com.
About Epilepsy Alliance America
Epilepsy Alliance America is a nation-wide network of community-based epilepsy organizations who are dedicated to confronting the spectrum of challenges created by seizures through the promotion of independence and quality of life for people with epilepsy and their families. The Alliance was founded in 2018 by eight leading grassroots epilepsy organizations who have unified in their mission to provide direct support to people with epilepsy, and the people who care for them. Members of Epilepsy Alliance America have been collectively supporting people with epilepsy for decades through support services, information, education, advocacy, and public awareness. As a result, the Alliance provides real epilepsy help to approximately 1 million Americans living with Epilepsy. Services provided by Member Organizations vary, but include educational programs in schools, individual/family consultations, legislative and special education advocacy, medication assistance, camp programs, and telephone support. For information about epilepsy support in your region, visit www.epilepsyallianceamerica.org.
The information set forth in this press release includes statements, estimates, projections with respect to our anticipated future performance and other forward-looking statements, which are subject to risks, uncertainties and assumptions. In some cases, you can identify these statements by forward-looking words such as "may", "might", "will", "should", "expect", "plan", "anticipate"
Investing in Regulation CF offerings involves a high degree of risk. Securities sold through Regulation CF Offerings are typically not publicly traded and, therefore, are less liquid. Additionally, investors will receive restricted stock that is subject to holding period requirements. Companies seeking capital through Regulation CF Offerings tend to be in earlier stages of development and have not yet been fully tested in the public marketplace. Investing in Regulation CF Offerings requires a tolerance for high risk, low liquidity, and a long-term commitment. Investors must be able to afford to lose their entire investment. Such investment products are not FDIC insured, may lose value, and have no bank guarantee.